PCPC Hatching Proposal For CIR Role In FDA Ingredient Review
This article was originally published in The Rose Sheet
The Personal Care Products Council has a vision for marrying the Cosmetic Ingredient Review’s expertise with FDA’s authority, which it hopes to package into reform legislation expected this year. While FDA has balked at formalizing CIR’s role under previous proposals, this one was inspired by a third-party review program for medical devices, making it potentially more palatable to the agency and lawmakers.
You may also be interested in...
The Cosmetic Ingredient Review says it expects to finalize a package of “advancements” in early 2020 to highlight the independence of its Expert Panel. Driven by the Personal Care Products Council-led CIR Steering Committee, the initiative comes at a time of escalating NGO criticism and legislative proposals that would undermine the CIR program and put its future in question.
The committee's discussion draft of cosmetics reform legislation combines elements of the proposed Personal Care Products Safety Act and FDA Cosmetic Safety and Modernization Act, but most closely aligns with the former. NGOs likely will be pleased; small businesses, perhaps not so much
Senator Orrin Hatch, R-Utah, introduces the FDA Cosmetic Safety and Modernization Act with the Personal Care Products Council's backing. The Environmental Working Group is opposed to the proposal, which falls considerably short of the draft Personal Care Products Safety Act, but the bill could unite big and small business, which were divided in the previous Congress with respect to regulatory reform legislation.